Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) / sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Weikersthal, L.F. von, Goebell, P.J., de Santis, M. de, Lerchenmüller, C., Zimmermann, U., Bos, M.M.E.M., Freier, W., Schirrmacher-Memmel, S., Staehler, M.D., Pahernik, S., Los, M., Schenck, M., Flörcken, A., van Arkel, C.V., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., Michel, M.S., 2014.

Oncol Res Treat 37 (suppl 5)(V28), 5. doi:10.1159/000368945

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
RCC-SWITCH
2014
Prognostic factors for overall survival in patients with advanced NSCLC – data from the clinical registry on lung cancer (TLK).

von Verschuer, U., Tessen, H.W., Eggert, J., Neise, M., Frank, M., Jänicke, M., Spring, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(V701), 227. doi:10.1159/000368945

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2014
Effectiveness of treatments for tumor-(therapy-) associated anemia in routine practice – data from the clinical tumor anemia registry (TAR).

Steinmetz, T., Köhler, A., Groschek, M., Koenigsmann, M., Vogt, M., Frank, M., Jänicke, M., 2014.

Oncol ResTreat 37 (suppl 5)(P534), 172. doi:10.1159/000368945

Abstract

Download

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TAR
2014
Real-life treatment and outcome data for patients with advanced NSCLC receiving treatments containing bevacizumab – data from the clinical registry on lung cancer (TLK).

Steffens, C.-C., Tessen, H.W., Losem, C., Münz, M., Jänicke, M., Spring, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(P217), 64. doi:10.1159/000368945

Abstract

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2014
Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer – data from the clinical TKK registry.

Schnell, R., Musch, R., Broszeit-Luft, S., Harde, J., Kopfmann, S., Jänicke, M., Marschner, N., 2014.

Oncol Res Treat 37(Suppl.5)(V332), 101. doi:10.1159/000368945

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2014
Patients with brain metastases from advanced or metastatic renal cell carcinoma – Data from the clinical RCC Registry.

Müller, L., Goebell, P., Reichert, D., Krieger, J., Jänicke, M., Harde, J., Koska, M., Marschner, N., 2014.

Oncol Res Treat 37 (suppl.5)(P287), 91. doi:10.1159/000368945

Abstract

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2014
No impact of first-line systemic therapy on quality of life of patients with metastatic breast cancer? Data from the MaLife-project.

Marschner, N., Tesch, H., Karcher, A., Ammon, A., Nusch, A., Boller, E., Spring, L., Jänicke, M., 2014.

Oncol Res Treat 37 (suppl 5)(V371), 111. doi:10.1159/000368945

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2014
Treatment of chemotherapy-induced neutropenia with Lipegfilgrastim (Lonquex®): First interim analysis of the non-interventional study NADIR.

Kurbacher, C., Diel, I., Egert, M., Fietz, T., Hurtz, H., Lück, A., Weide, R., Wolff, T., Zaiss, M., Teichmann, B., Harde, J., Scheuerlein, R., 2014.

Oncol Res Treat 37(suppl 5)(P512). doi:10.1159/000368945

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2014
1st-line treatment with BR and FCR in patients with chronic lymphocytic leukamia.

Knauf, W., Abenhardt, W., Engel, E., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2014.

Oncol Res Treat 37 (suppl5)(P186), 50. doi:10.1159/000368945

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2014
Long-term side effects of curative treatment for breast cancer – data from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(V370), 110. doi:10.1159/000368945

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2014